SciBX: Science-Business eXchange Contents: June 20 2013, Volume 6 / Issue 24

TABLE OF CONTENTS June 20 2013, Volume 6 / Issue 24 Analysis Cover Story Targets and Mechanisms Tools The Distillery: Therapeutics Autoimmune disease Cancer Cardiovascular disease Dermatology Endocrine/metabolic disease Inflammation Neurology Pulmonary disease The Distillery: Techniques Disease models Drug platforms Markers Advertisement Biopharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery The April 2013 issue of Biopharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with Johnson & Johnson.   Analysis Cover Story Top Interfacing with Ras Amy Donner doi:10.1038/scibx.2013.588 A German team has identified a compound that disrupts a protein-protein interaction that localizes K-Ras to the cell membrane, thus selectively inhibiting tumor growth. The interface provides a new small molecule binding site for the handful of companies and academics working on ways to tackle the previously undruggable Ras family. Full Text | PDF Targets and Mechanisms Top Rationalizing CF combos Chris Cain doi:10.1038/scibx.2013.589 A McGill University–led team has shown that CFTR corrector compounds target only one of two sequential steps required for proper folding of the mutated protein. The findings suggest there is a clear rationale for developing combinations of correctors to treat patients with cystic fibrosis. Full Text | PDF FGF9 for baldness Lauren Martz doi:10.1038/scibx.2013.590 A University of Pennsylvania team has found that increasing FGF9 levels in wounded skin can promote the growth of hair follicles in mice. Follica has licensed the findings and plans to test the effects of FGF9 in hair growth indications. Full Text | PDF Tools Top Transferring flu protection Tracey Baas doi:10.1038/scibx.2013.591 Two independent studies provide proof of concept that gene transfer could be used to establish broad protection against influenza. Both groups are working to move their influenza A virus hemagglutinin–expressing vectors into humans. Full Text | PDF Distillery: Therapeutics Autoimmune disease Top Tyrosine kinase 2 (TYK2) doi:10.1038/scibx.2013.592 In vitro and rodent studies suggest selectively inhibiting TYK2 could help treat IBD and psoriasis. Full Text | PDF Cancer Top Apolipoprotein A-1 (APOA1) doi:10.1038/scibx.2013.593 Mouse studies suggest APOA1 could help treat solid tumors. Full Text | PDF Eukaryotic translation elongation factor 2 kinase (EEF2K) doi:10.1038/scibx.2013.594 Patient, mouse and cell culture studies suggest inhibiting EEF2K could help improve the efficacy of nutrient deprivation therapy for cancer. Full Text | PDF Neuropilin 2 (NRP2) doi:10.1038/scibx.2013.595 Patient sample and mouse studies suggest inhibiting NRP2 could help prevent cancer metastasis. Full Text | PDF Ninjurin 1 (NINJ1) doi:10.1038/scibx.2013.596 Cell culture studies suggest inhibiting NINJ1 could help treat cancer. Full Text | PDF BRAF doi:10.1038/scibx.2013.597 Patient studies suggest Zelboraf vemurafenib could help treat BRAF V600E mutant MM. Full Text | PDF Cardiovascular disease Top Dickkopf homolog 1 (DKK1) doi:10.1038/scibx.2013.598 Cell culture studies suggest inhibiting DKK1 could help treat atherosclerosis. Full Text | PDF Complement component 3a receptor 1 (C3AR1; C3AR) doi:10.1038/scibx.2013.599 Mouse studies suggest C3AR agonists could help treat ischemia/reperfusion injury. Full Text | PDF NADH dehydrogenase subunit 3 (ND3; MT-ND3) doi:10.1038/scibx.2013.600 In vitro and mouse studies suggest S-nitrosylation of MT-ND3 could help prevent ischemia/reperfusion injury. Full Text | PDF Dermatology Top B-type natriuretic peptide (BNP; NPPB); natriuretic peptide receptor A (NPR1; NPRA) doi:10.1038/scibx.2013.601 Mouse studies suggest inhibiting NPPB or NPRA could help treat itch. Full Text | PDF Endocrine/metabolic disease Top Solute carrier family 10 sodium-dependent bile acid transporter member 2 (SLC10A2; ASBT; IBAT) doi:10.1038/scibx.2013.602 In vitro and rodent studies identified benzothiazepine ASBT inhibitors that could help treat diabetes. Full Text | PDF Branched chain ketoacid dehydrogenase kinase (BCKDK; BDK) doi:10.1038/scibx.2013.603 In vitro and mouse studies identified a BDK inhibitor that could help treat diseases associated with accumulation of branched-chain amino acids (BCAAs), including the genetic disorder branched-chain ketoaciduria, obesity and diabetes. Full Text | PDF Inflammation Top Leukotriene B4 (LTB4); complement 5 (C5) doi:10.1038/scibx.2013.604 In vitro and mouse studies suggest inhibitors of both C5 and LTB4 could help treat inflammatory diseases. Full Text | PDF Neurology Top Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) doi:10.1038/scibx.2013.605 Mouse studies suggest omigapil and other inhibitors of GAPDH nitrosylation could help treat cocaine addiction or overdose. Full Text | PDF Semaphorin 4D (SEMA4D) doi:10.1038/scibx.2013.606 Cell and tissue culture studies suggest SEMA4D-Fc could be used to treat epilepsy. Full Text | PDF Dopamine D2 receptor; dopamine D3 receptor; serotonin (5-HT1A) receptor; serotonin (5-HT1B) receptor doi:10.1038/scibx.2013.607 In vitro and rodent studies suggest coumarin piperazine derivatives could be useful for treating psychosis. Full Text | PDF Pulmonary disease Top Mucin 5B oligomeric mucus/gel-forming (MUC5B) doi:10.1038/scibx.2013.608 Patient studies suggest the rs35705950 SNP in the MUC5B promoter region could be a marker of interstitial lung disease risk. Full Text | PDF Distillery: Techniques Disease models Top A microchip platform to model heart failure doi:10.1038/scibx.2013.609 A microchip platform could be used to model failing myocardium and identify molecules to prevent myocardial infarction (MI) or hypertension. Full Text | PDF Drug platforms Top Live, attenuated influenza A virus with suppressed hemagglutinin (HA) and neuraminidase (NA) expression as a vaccine doi:10.1038/scibx.2013.610 Live, attenuated influenza A virus with suppressed HA and NA expression could be used to develop vaccines. Full Text | PDF mAb antagonists against glucose-dependent insulinotropic polypeptide receptor (GIPR) doi:10.1038/scibx.2013.611 mAb antagonists against GIPR could be useful as tools to develop improved inhibitors and study receptor function in human disease. Full Text | PDF Self-assembling influenza nanoparticle vaccines doi:10.1038/scibx.2013.612 Self-assembling influenza nanoparticles could be used as vaccines to induce broadly neutralizing antibodies. Full Text | PDF Markers Top Nuclear localization status of nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2) to distinguish essential thrombocythemia (ET) and primary myelofibrosis (MF) doi:10.1038/scibx.2013.613 The nuclear localization status of NRF2 could help differentiate between the myeloproliferative disorders ET and primary MF. Full Text | PDF Peptidyl arginine deiminase type III (PADI3; PAD3) autoantibodies as a prognostic marker for rheumatoid arthritis (RA) doi:10.1038/scibx.2013.614 Patient sample studies suggest autoantibodies that recognize PAD3 and activate PAD4 (PADI4) could be used to identify patients at risk for radiographic progression in RA. Full Text | PDF Top Advertisement SciBX: Science Business eXchange Innovation in Drug Discovery Challenge: Harnessing Endocytosis for Drug Discovery SciBX, in partnership with Innocentive, is requesting ideas from the scientific community to progress the understanding of how large therapeutic molecules can effectively intercept and use the endocytosis process to achieve class-wide cell permeability. Click here to find out more!   Advertisement Nature Publishing Group and Relay Technology Management present: The Epigenetics Target Explorer Click here to access this free online tool and the accompanying article in Nature Reviews Drug Discovery.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.